Hubrecht RC, Carter E. The 3Rs and Humane experimental technique: implementing change. Anim Open Access J MDPI. sept 2019;30(10):754.

Wadman M. FDA no longer has to require animal testing for new drugs. Sci 13 janv. 2023;379(6628):127–8.

CAS  Google Scholar 

Jensen C, Teng Y. Is it Time to start transitioning from 2D to 3D cell culture? Front Mol Biosci 6 mars 2020;7.

Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N et al. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers [Internet]. juin 2020 [cité 23 mai 2024];12(6). Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352800/

Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch Med Sci [Internet]. 2016. https://doi.org/10.5114/aoms.2016.63743. [cité 23 mai 2024]; Disponible sur:. https://www.termedia.pl/doi/.

Article  PubMed  Google Scholar 

Sato T, Stange DE, Ferrante M, Vries RGJ, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterol Nov. 2011;141(5):1762–72.

Article  CAS  Google Scholar 

Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids Nat Rev Methods Primer 1 déc. 2022;2(1):94.

Article  CAS  Google Scholar 

Engel RM, Jardé T, Oliva K, Kerr G, Chan WH, Hlavca S, et al. Modeling colorectal cancer: a bio-resource of 50 patient-derived organoid lines. J Gastroenterol Hepatol Mai. 2022;37(5):898–907.

Article  CAS  Google Scholar 

Lv T, Shen L, Xu X, Yao Y, Mu P, Zhang H, et al. Patient-derived tumor organoids predict responses to irinotecan‐based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Int J Cancer févr. 2023;152(3):524–35.

Article  CAS  Google Scholar 

Cho YW, Min DW, Kim HP, An Y, Kim S, Youk J, et al. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer. Mol Oncol juin. 2022;16(12):2396–412.

Article  Google Scholar 

Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 24 Juill. 2018;18(7):407–18.

Article  CAS  Google Scholar 

Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between Immune landscapes, genetic subtypes and responses to Immunotherapy in Colorectal Cancer. Front Immunol 6 mars. 2020;11:369.

Article  CAS  Google Scholar 

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer févr. 2017;17(2):79–92.

Article  CAS  Google Scholar 

Zheng Z, Wieder T, Mauerer B, Schäfer L, Kesselring R, Braumüller H. T cells in Colorectal Cancer: unravelling the function of different T cell subsets in the Tumor Microenvironment. Int J Mol Sci. 2023.

Roelands J, Kuppen P, Vermeulen L, Maccalli C, Decock J, Wang E, et al. Immunogenomic classification of Colorectal Cancer and therapeutic implications. Int J Mol Sci. oct 2017;24(10):2229.

He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G et al. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Front Bioeng Biotechnol 22 mai 2023;11.

Wang T, Pan W, Zheng H, Zheng H, Wang Z, Li JJ, et al. Accuracy of using a patient-derived Tumor Organoid Culture Model to predict the response to Chemotherapy regimens in Stage IV Colorectal Cancer: a blinded study. Dis Colon Rectum 1 Juill. 2021;64(7):833–50.

Article  Google Scholar 

Sakshaug BC, Folkesson E, Haukaas TH, Visnes T, Flobak Å. Systematic review: predictive value of organoids in colorectal cancer. Sci Rep 23 oct. 2023;13(1):18124.

Article  CAS  Google Scholar 

Ramzy GM, Norkin M, Koessler T, Voirol L, Tihy M, Hany D, et al. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. J Exp Clin Cancer Res 3 avr. 2023;42(1):79.

Article  CAS  Google Scholar 

Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived Organoids Predict Chemoradiation responses of locally advanced rectal Cancer. Cell Stem Cell 2 janv. 2020;26(1):17–e266.

Article  CAS  Google Scholar 

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Sci 23 févr. 2018;359(6378):920–6.

CAS  Google Scholar 

Mo S, Tang P, Luo W, Zhang L, Li Y, Hu X, et al. Patient-derived Organoids from Colorectal Cancer with Paired Liver Metastasis reveal Tumor heterogeneity and predict response to Chemotherapy. Adv Sci Weinh Baden-Wurtt Ger Nov. 2022;9(31):e2204097.

Google Scholar 

Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, et al. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. ESMO Open juin. 2023;8(3):101198.

Article  CAS  Google Scholar 

Ooft SN, Weeber F, Schipper L, Dijkstra KK, McLean CM, Kaing S, et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open juin. 2021;6(3):100103.

Article  CAS  Google Scholar 

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget 6 juin. 2017;8(23):38022–43.

Article  Google Scholar 

Özdemir D, Büssgen M. Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma. J Pharm Policy Pract 25 sept. 2023;16:106.

Article  Google Scholar 

Antolin A, Workman P, Mestres J, Al-Lazikani B. Polypharmacology in Precision Oncology: current applications and future prospects. Curr Pharm Des 24 janv. 2017;22(46):6935–45.

Article  Google Scholar 

Yang J, Kang H, Lyu L, Xiong W, Hu Y. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov. Discov Oncol 21 août. 2023;14(1):151.

Article  CAS  Google Scholar 

Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential impact of the Multi-target Drug Approach in the treatment of some Complex diseases. Drug Des Devel Ther 11 août. 2020;14:3235–49.

Article  CAS  Google Scholar 

Matsubara H, Miyoshi H, Kakizaki F, Morimoto T, Kawada K, Yamamoto T, et al. Efficacious combination Drug Treatment for Colorectal Cancer that overcomes resistance to KRAS G12C inhibitors. Mol Cancer Ther 3 avr. 2023;22(4):529–38.

Article  CAS  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw mars. 2021;19(3):329–59.

Article  Google Scholar 

Weiss A, Nowak-Sliwinska P. Current trends in Multidrug optimization: an Alley of future successful treatment of Complex disorders. SLAS Technol juin. 2017;22(3):254–75.

Article  Google Scholar 

Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 18 déc. 2023;8(1):1–38.

Google Scholar 

Shahi Thakuri P, Lamichhane A, Singh S, Gupta M, Luker GD, Tavana H. Modeling Adaptive Resistance of KRAS Mutant Colorectal Cancer to MAPK Pathway Inhibitors with a Three-Dimensional Tumor Model. ACS Pharmacol Transl Sci. 11 déc. 2020;3(6):1176–87.

Zoetemelk M, Ramzy GM, Rausch M, Koessler T, van Beijnum JR, Weiss A, et al. Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Mol Oncol 1 nov. 2020;14(11):2894–919.

Article  CAS  Google Scholar 

Atanasova VS, Riedl A, Strobl M, Flandorfer J, Unterleuthner D, Weindorfer C et al. Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition. Int J Mol Sci. 14 janv. 2023;24(2):1668.

Weiss A, Le Roux-Bourdieu M, Zoetemelk M, Ramzy GM, Rausch M, Harry D, et al. Identification of a synergistic multi-drug combination active in Cancer cells via the Prevention of Spindle Pole Clustering. Cancers. oct 2019;22(10):1612.

Thng DKH, Hooi L, Siew BE, Lee KY, Tan IJW, Lieske B et al. A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids. Npj Precis Oncol. 27 févr. 2024;8(1):52.

Bubna AK. Vorinostat—An overview. Indian J Dermatol. 2015;60(4):419.

Article  PubMed  PubMed Central  Google Scholar 

Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, et al. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell Rep 25 avr. 2023;42(4):112324.

Article  CAS  Google Scholar 

Bitar L, Zouein J, Haddad FG, Eid R, Kourie HR. HER2 in metastatic colorectal cancer: a new to target to remember. Biomark Med févr. 2021;15(2):135–8.

Article  Google Scholar 

Zeiser R, Andrlová H, Meiss F. Trametinib (GSK1120212). Recent Results Cancer Res Fortschr Krebsforsch Progres Dans Rech Sur Cancer. 2018;211:91–100.

Article  CAS  Google Scholar 

Wang Q, Shen X, Chen G, Du J. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers. 14 juin. 2022;14(12):2928.

Guo Y, Wang M, Zou Y, Jin L, Zhao Z, Liu Q et al. Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer. J Nanobiotechnology. 11 août. 2022;20(1):371.

Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. sept 2018;14(34):3834–48.

Zoetemelk M, Ramzy GM, Rausch M, Nowak-Sliwinska P. Drug-drug interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and its activity in Colorectal Carcinoma Treatment. Molecules 4 juin. 2020;25(11):2614.

Article  CAS  Google Scholar 

Ramzy GM, Boschung L, Koessler T, Delucinge-Vivier C, Docquier M, McKee TA et al. FOLFOXIRI Resistance induction and characterization in human colorectal Cancer cells. Cancers. 1 oct 2022;14(19).

Boos SL, Loevenich LP, Vosberg S, Engleitner T, Öllinger R, Kumbrink J, et al. Disease modeling on Tumor Organoids implicates AURKA as a therapeutic target in Liver metastatic colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2022;13(2):517–40.

Article  CAS  PubMed  Google Scholar 

Liewer S, Huddleston A. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. Expert Opin Investig Drugs janv. 2018;27(1):105–12.